Literature DB >> 7238568

Enzymatic oxidation of polyamines. Relationship to immunosuppressive properties.

R S Labib, T B Tomasi.   

Abstract

A method for the detection of spermine oxidase activity was developed using the amino acid analyzer to follow the changes in composition of incubation mixture of spermine or spermidine. Spermine oxidase activity could be detected in fetal calf serum (FCS), and six major spermine oxidation products were revealed in the incubation mixture. Incubation of spermine or spermidine with FCS produced oxidation products which suppressed lipopolysaccharide-induced mitogenesis and the murine mixed lymphocyte reaction. Oxidation was inhibited by the spermine oxidase inhibitors hydroxylamine and isonicotinic acid hydrazide, and inhibition of the immune response was no longer evident suggesting that the inhibitory material was a product of the action of the enzyme on spermic and spermidine. When FCS was used as the source of the spermine oxidase, some suppression via a cytotoxic effect could not be excluded. Mouse amniotic fluid was found to contain high levels of a spermine oxidase having a somewhat different specificity than that in FCS, and this enzyme produced a noncytotoxic immune inhibitor from cadaverine, spermidine and spermine. These data raise questions concerning the role polyamine oxidation products may play in the immunosuppression associated with pregnancy and in the generation of nonantigen-specific suppressors by cells cultured in FCS or other media containing polyamine oxidase activity.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7238568     DOI: 10.1002/eji.1830110318

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  11 in total

1.  The identification of factors in seminal plasma responsible for suppression of natural killer cell activity.

Authors:  P J Vallely; R M Sharrard; R C Rees
Journal:  Immunology       Date:  1988-03       Impact factor: 7.397

2.  Increased polyamines may downregulate interleukin 2 production in rheumatoid arthritis.

Authors:  E Flescher; T L Bowlin; A Ballester; R Houk; N Talal
Journal:  J Clin Invest       Date:  1989-04       Impact factor: 14.808

3.  Elevated epidermal ornithine decarboxylase activity suppresses contact hypersensitivity.

Authors:  Martin P Keough; Candace S Hayes; Karen DeFeo; Susan K Gilmour
Journal:  J Invest Dermatol       Date:  2010-09-16       Impact factor: 8.551

4.  Polyamine-blocking therapy reverses immunosuppression in the tumor microenvironment.

Authors:  Candace S Hayes; Allyson C Shicora; Martin P Keough; Adam E Snook; Mark R Burns; Susan K Gilmour
Journal:  Cancer Immunol Res       Date:  2013-10-07       Impact factor: 11.151

5.  Regulation of IL-2 production by mononuclear cells from rheumatoid arthritis synovial fluids.

Authors:  E Flescher; T L Bowlin; N Talal
Journal:  Clin Exp Immunol       Date:  1992-03       Impact factor: 4.330

6.  Polyamines in clinical disorders.

Authors:  D F Tierney; L J Marton; A D Hacker; N Lowe
Journal:  West J Med       Date:  1985-01

7.  Metabolites Involved in Immune Evasion by Batrachochytrium dendrobatidis Include the Polyamine Spermidine.

Authors:  Louise A Rollins-Smith; Antonio C Ruzzini; J Scott Fites; Laura K Reinert; Emily M Hall; Bryan A Joosse; Vishvaas I Ravikumar; Megan I Huebner; Audrey Aka; Miles H Kehs; Bria M Gillard; Emily Doe; Julia A Tasca; Thomas P Umile; Jon Clardy; Kevin P C Minbiole
Journal:  Infect Immun       Date:  2019-04-23       Impact factor: 3.441

8.  Seminal plasma suppression of human lymphocyte responses in vitro requires the presence of bovine serum factors.

Authors:  P J Vallely; R C Rees
Journal:  Clin Exp Immunol       Date:  1986-10       Impact factor: 4.330

9.  The mechanism of the inhibitory effect of polyamines on the induction of nitric oxide synthase: role of aldehyde metabolites.

Authors:  C Szabó; G J Southan; C Thiemermann; J R Vane
Journal:  Br J Pharmacol       Date:  1994-11       Impact factor: 8.739

10.  A novel polyamine blockade therapy activates an anti-tumor immune response.

Authors:  Eric T Alexander; Allyson Minton; Molly C Peters; Otto Phanstiel; Susan K Gilmour
Journal:  Oncotarget       Date:  2017-08-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.